EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Early On-Treatment Ultrasound Tumor Shrinkage and HER2-Positive Residual Invasive Disease After Neoadjuvant Therapy: A 2-Center Study

Chi Zhang, Lin Zhou, Lingfeng Tang, Zijian Wang, Shunbo Li, Yimei Tang, Chunxiang Tian, Zeyu Liu, Shengchun Liu

Clinical Breast Cancer · 2026-11 · 26 (11) · 48-57

DOI: 10.1016/j.clbc.2026.09.006 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Breast Cancer, 2026-11. Verfasst von Chi Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing …. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Neoplasm, Residual. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chongqing Medical University, National Natural Science Foundation of China, Science-Health Joint Medical Scientific Research Project of Chongqing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyErb-b2 Receptor Tyrosine KinasesBreast NeoplasmsNeoplasm, ResidualUltrasonography, MammaryAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesMiddle AgedPathologic Complete ResponseAdultAgedBiomarkers, TumorBreast

Stichwörter der Autor:innen

HER2-positive breast cancerPrediction modelResponse assessmentRisk stratificatioUltrasonography

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
  • Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. Electronic address: tiancx.cd@qq.com.
  • Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. Electronic address: 37781380@qq.com.
  • Department of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: liushengchun…

Förderung

  • Chongqing Medical University
  • National Natural Science Foundation of China
  • Science-Health Joint Medical Scientific Research Project of Chongqing

Zitieren

APA

Zhang, C., Zhou, L., Tang, L., Wang, Z., Li, S., Tang, Y., Tian, C., Liu, Z., & Liu, S. (2026). Early On-Treatment Ultrasound Tumor Shrinkage and HER2-Positive Residual Invasive Disease After Neoadjuvant Therapy: A 2-Center Study. Clinical Breast Cancer, 26(11), 48-57. https://doi.org/10.1016/j.clbc.2026.09.006

Vancouver

Zhang C, Zhou L, Tang L, Wang Z, Li S, Tang Y, et al. Early On-Treatment Ultrasound Tumor Shrinkage and HER2-Positive Residual Invasive Disease After Neoadjuvant Therapy: A 2-Center Study. Clinical Breast Cancer. 2026;26(11):48-57. doi:10.1016/j.clbc.2026.09.006

BibTeX
@article{Zhang2026,
  author = {Zhang, Chi and Zhou, Lin and Tang, Lingfeng and Wang, Zijian and Li, Shunbo and Tang, Yimei and Tian, Chunxiang and Liu, Zeyu and Liu, Shengchun},
  title = {Early On-Treatment Ultrasound Tumor Shrinkage and HER2-Positive Residual Invasive Disease After Neoadjuvant Therapy: A 2-Center Study},
  journal = {Clinical Breast Cancer},
  year = {2026},
  volume = {26},
  number = {11},
  pages = {48--57},
  doi = {10.1016/j.clbc.2026.09.006}
}
Kostenlos starten →